Antimicrobial Agents Practice Questions

Q: All of the following are used for treatment of *H. pylori*, except:

Gentamicin. ***Gentamicin*** - **Gentamicin** is an **aminoglycoside antibiotic** primarily used for severe Gram-negative bacterial infections and is **not effective** against *H. pylori*. - Its mechanism of action and **toxicity profile** (ototoxicity, nephrotoxicity) make it unsuitable for typical *H. pylori* eradication regimens. *Clarithromycin* - **Clarithromycin** is a **macrolide antibiotic** frequently used in **triple therapy regimens** for *H. pylori* eradication. - It works by **inhibiting bacterial protein synthesis**, significantly contributing to the eradication of the bacteria. *Metronidazole* - **Metronidazole** is an **antibiotic** and **antiprotozoal agent** commonly included in *H. pylori* **quadruple therapy** or when penicillin allergies are present. - It acts by forming **cytotoxic compounds** that disrupt bacterial DNA, making it effective against anaerobic and microaerophilic bacteria like *H. pylori*. *Amoxicillin* - **Amoxicillin** is a **beta-lactam antibiotic** that is a cornerstone of many *H. pylori* **eradication regimens**, particularly in standard triple therapy. - It works by **inhibiting bacterial cell wall synthesis**, leading to bacterial lysis.

Q: What is the drug of choice for listeria meningitis?

Ampicillin. ***Ampicillin*** - **Ampicillin** is the **drug of choice** for *Listeria monocytogenes* meningitis due to its excellent in vitro activity and good central nervous system penetration. - It is often used in combination with an **aminoglycoside** (e.g., gentamicin) for synergistic bactericidal activity, especially in severe cases, though gentamicin does not penetrate the CSF well. *Cefotaxime* - **Third-generation cephalosporins** like cefotaxime have poor activity against *Listeria monocytogenes* due to the organism's intrinsic resistance to these agents. - While effective against many other bacterial causes of meningitis (e.g., *S. pneumoniae*, *N. meningitidis*), it is not appropriate for *Listeria*. *Ceftriaxone* - Similar to cefotaxime, **ceftriaxone** is a third-generation cephalosporin and is **ineffective** against *Listeria monocytogenes* due to the lack of penicillin-binding protein (PBP) affinity. - Its use for *Listeria* meningitis would lead to treatment failure. *Ciprofloxacin* - **Ciprofloxacin**, a fluoroquinolone, is generally **not recommended** as a first-line treatment for *Listeria* meningitis, despite some in vitro activity. - Its use is typically reserved for patients with severe allergies to penicillins, and even then, **trimethoprim-sulfamethoxazole** is usually preferred as an alternative to ampicillin.

Q: What is the primary purpose of administering a multidrug regimen for tuberculosis (TB) treatment?

To prevent the development of drug resistance. ***To prevent the development of drug resistance*** - Using multiple drugs simultaneously targets different bacterial pathways, reducing the likelihood of *Mycobacterium tuberculosis* evolving resistance to any single drug [1] - This strategy ensures that even if a few bacteria are naturally resistant to one drug, other drugs in the regimen will eliminate them [1] - This is the fundamental principle behind multidrug TB therapy as per WHO guidelines *To provide broad-spectrum coverage* - TB treatment uses multiple drugs specifically against *Mycobacterium tuberculosis*, not for broad-spectrum coverage [2] - These regimens are tailored to the known characteristics of TB bacteria, not to cover a wide range of pathogens [2] - The drugs used (rifampicin, isoniazid, pyrazinamide, ethambutol) are relatively specific for mycobacteria [2] *To minimize side effects* - Administering multiple anti-TB drugs actually increases the risk of cumulative side effects due to drug interactions and individual toxicities [3] - Each drug has its own toxicity profile (hepatotoxicity, optic neuritis, hyperuricemia) [3] - While side effects are monitored, minimizing them is not the primary reason for multidrug approach *To ensure treatment adherence* - Treatment adherence refers to the patient's consistent use of prescribed medications, not the number of drugs - A complex multidrug regimen can actually make adherence more challenging - Directly Observed Therapy (DOT) is often needed to improve adherence with multidrug regimens

Q: What is the primary reason for using a combination of four drugs in Anti-Koch's Treatment (AKT) for tuberculosis?

To decrease the risk of resistance due to mutation.. ***To decrease the risk of resistance due to mutation*** - **Tuberculosis bacteria** can spontaneously develop resistance to a single drug through **random genetic mutations**. - Using multiple drugs simultaneously significantly reduces the probability that a bacterium will spontaneously develop resistance to **all drugs** in the regimen. - This is the **primary rationale** for multi-drug therapy in TB, as emphasized by WHO guidelines. *To decrease the risk of resistance due to conjugation* - **Conjugation** is a mechanism of horizontal gene transfer in bacteria, primarily involving the transfer of plasmids. - While important for antibiotic resistance in some bacteria, it is **not the primary mechanism** of resistance development in *Mycobacterium tuberculosis*. - TB resistance develops mainly through **chromosomal mutations**, not plasmid transfer. *To enhance overall treatment efficacy* - While multi-drug regimens do enhance treatment efficacy by targeting different bacterial populations (actively dividing, slow-growing, dormant), this is a **consequence** of the multi-drug approach. - The **primary reason** for using four drugs specifically is to prevent the emergence of **drug-resistant mutants**. - Enhanced efficacy is achieved *because* resistance is prevented, making this a secondary benefit. *To simplify treatment* - A four-drug regimen actually makes treatment more **complex** due to multiple pills, potential drug interactions, and increased side effects. - The complexity is a necessary trade-off for **resistance prevention** and treatment success.

Q: Which of the following antibiotics is known to cause bleeding due to its effect on blood clotting?

Moxalactam. Moxalactam - Moxalactam is a **third-generation cephalosporin** known to cause **hypoprothrombinemia** and platelet dysfunction, leading to an increased risk of bleeding. - This effect is due to its **N-methylthiotetrazole (NMTT) side chain**, which inhibits vitamin K-dependent clotting factor synthesis. Cefaloridine - This is a **first-generation cephalosporin** that does not have the NMTT side chain and is not commonly associated with significant bleeding risks. - Its primary adverse effect of concern is **nephrotoxicity** at high doses, rather than coagulopathy. Ceftazidime - Ceftazidime is a **third-generation cephalosporin** primarily used for *Pseudomonas aeruginosa* infections but does **not contain the NMTT side chain** responsible for bleeding complications. - While broad-spectrum, it generally has a favorable safety profile concerning coagulation. *Cefazolin* - Cefazolin is a **first-generation cephalosporin** [1] widely used for surgical prophylaxis and skin infections [1], and it does **not interfere with coagulation** pathways. - Its main side effects are typical for penicillin-related antibiotics, such as hypersensitivity reactions [1],[2].

Q: What is the recommended dose of oseltamivir for a child aged 9 months?

3 mg/kg twice daily for 5 days. ***3 mg/kg twice daily for 5 days*** - For children aged **less than 1 year**, and weighing less than 15 kg, the recommended oseltamivir dose is **3 mg/kg** administered **twice daily** for 5 days. - This dosage regimen is effective in treating influenza and is based on studies of its **pharmacokinetics** and **efficacy** in this age group. *2 mg/kg twice daily for 5 days* - This dosage is **lower than recommended** for children under 1 year of age and may not achieve adequate therapeutic drug levels. - Subtherapeutic dosing could lead to **reduced antiviral efficacy** and potentially poorer clinical outcomes. *2.5 mg/kg twice daily for 5 days* - Similar to the 2 mg/kg dose, this is **below the standard recommendation** for infants and young children in this age bracket. - Inadequate dosing increases the risk of **treatment failure** and the development of **antiviral resistance**. *3.5 mg/kg twice daily for 5 days* - This dosage might be considered **higher than necessary** for a 9-month-old child and could potentially increase the risk of **adverse effects**. - While exact toxicities are rare within a reasonable range, adherence to recommended guidelines optimizes the **benefit-risk profile**.

Q: Sulphonamide injection causes decrease in folic acid by?

Inhibition through competition with substrate. ***Inhibition through competition with substrate***Sulphonamides are **structural analogs of p-aminobenzoic acid (PABA)**, a substrate crucial for dihydropteroate synthase [1, 2]. They competitively inhibit this enzyme, which synthesizes **dihydrofolic acid**, a precursor to **tetrahydrofolic acid (THF)**, thereby reducing folic acid production in bacteria [1, 2].*Inhibition without competition*This typically refers to **non-competitive inhibition**, where the inhibitor binds to an allosteric site and changes the enzyme's conformation, regardless of substrate concentration. Sulphonamides, however, specifically compete with PABA at the active site of **dihydropteroate synthase**.*Inhibition through a different site*This describes **allosteric inhibition** or non-competitive inhibition, where the inhibitor binds to a site other than the active site. Sulphonamides do not work through an allosteric mechanism; they directly interfere with the binding of PABA at the enzyme's active site.*Inhibition that does not involve the active site*This is another way to describe **non-competitive** or **allosteric inhibition**, where the inhibitor binds elsewhere on the enzyme, altering its function without directly blocking the active site. Sulphonamides' mechanism is distinct, as they closely resemble the natural substrate and directly compete for the active site of **dihydropteroate synthase**.

Q: Which of the following drugs is not used for prophylaxis against malaria?

Artesunate. Artesunate - **Artesunate** is a **fast-acting artemisinin derivative primarily used for treating acute malaria infections, especially severe or complicated cases**, and is not recommended for prophylaxis [4]. - Its short half-life and rapid clearance make it unsuitable for preventing malaria, as it would require frequent dosing, which is impractical for long-term prevention. *Doxycycline* - **Doxycycline** is an **antibiotic** that can be used for malaria prophylaxis, particularly in areas with **chloroquine-resistant P. falciparum** [1]. - It works by inhibiting protein synthesis in the parasite and must be taken daily, starting before travel and continuing for a period after returning [1]. *Chloroquine* - **Chloroquine** was historically a cornerstone for malaria prophylaxis due to its effectiveness and low cost, particularly in areas with **sensitive Plasmodium species.** [2] - However, widespread **chloroquine resistance**, especially in **P. falciparum**, has limited its current use for prophylaxis to specific regions where resistance is not prevalent [2]. *Mefloquine* - **Mefloquine** is an **antimalarial drug** commonly used for prophylaxis, especially in areas with **chloroquine-resistant P. falciparum** [2], [3]. - It is known for its convenience of once-weekly dosing but can have significant **neuropsychiatric side effects**, limiting its use in some individuals [3].

Q: As per RNTCP guidelines, Multi drug resistance (MDR) TB is defined as resistance to:

Rifampicin and isoniazid. ***Rifampicin and isoniazid*** - According to **RNTCP guidelines** (now NTEP), **MDR-TB** is specifically defined as tuberculosis that is resistant to at least both **rifampicin** and **isoniazid**. - These two drugs are the **most potent first-line anti-TB medications**, and resistance to both significantly complicates treatment. *Rifampicin* - While resistance to **rifampicin alone** is a serious concern, it is classified as **rifampicin-resistant TB (RR-TB)**, not full **MDR-TB**. - **MDR-TB** requires resistance to at least two key first-line drugs. *Rifampicin, isoniazid and ethambutol* - Resistance to **rifampicin**, **isoniazid**, and **ethambutol** would be a form of **MDR-TB** (as it includes resistance to rifampicin and isoniazid), but it is a more extensive form of resistance. - The minimum definition of **MDR-TB** focuses on the two most crucial first-line drugs. *None of the above* - This option is incorrect because there is a specific definition for **MDR-TB** that aligns with one of the provided choices. - The guidelines clearly define **MDR-TB** based on resistance to specific drugs.

Question 1

What is the best skin disinfectant for central line insertion?

Accepted Answer

Chlorhexidine

Answer

Alcohol

Answer

Cetrimide

Answer

Povidone iodine

Question 2

All of the following are used for treatment of *H. pylori*, except:

Accepted Answer

Gentamicin

Answer

Metronidazole

Answer

Amoxicillin

Answer

Clarithromycin

Question 3

What is the drug of choice for listeria meningitis?

Accepted Answer

Ampicillin

Answer

Cefotaxime

Answer

Ciprofloxacin

Answer

Ceftriaxone

Question 4

What is the primary purpose of administering a multidrug regimen for tuberculosis (TB) treatment?

Accepted Answer

To prevent the development of drug resistance

Answer

To provide broad-spectrum coverage

Answer

To minimize side effects

Answer

To ensure treatment adherence

Question 5

What is the primary reason for using a combination of four drugs in Anti-Koch's Treatment (AKT) for tuberculosis?

Accepted Answer

To decrease the risk of resistance due to mutation.

Answer

To decrease the risk of resistance due to conjugation.

Answer

To enhance overall treatment efficacy.

Answer

To simplify treatment.

Question 6

Which of the following antibiotics is known to cause bleeding due to its effect on blood clotting?

Accepted Answer

Moxalactam

Answer

Cefaloridine

Answer

Cefazolin

Answer

Ceftazidime

Question 7

What is the recommended dose of oseltamivir for a child aged 9 months?

Accepted Answer

3 mg/kg twice daily for 5 days

Answer

2 mg/kg twice daily for 5 days

Answer

2.5 mg/kg twice daily for 5 days

Answer

3.5 mg/kg twice daily for 5 days

Question 8

Sulphonamide injection causes decrease in folic acid by?

Accepted Answer

Inhibition through competition with substrate

Answer

Inhibition without competition

Answer

Inhibition through a different site

Answer

Inhibition that does not involve the active site

Question 9

Which of the following drugs is not used for prophylaxis against malaria?

Accepted Answer

Artesunate

Answer

Doxycycline

Answer

Mefloquine

Answer

Chloroquine

Question 10

As per RNTCP guidelines, Multi drug resistance (MDR) TB is defined as resistance to:

Accepted Answer

Rifampicin and isoniazid

Answer

Rifampicin

Answer

Rifampicin, isoniazid and ethambutol

Answer

None of the above

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?